Home > Biological Science > Immunobiology > Volume-10 > Issue-4 > Fucoidan as a Marine-Derived Therapeutic: From Molecular Mechanisms to Clinical Applications

Fucoidan as a Marine-Derived Therapeutic: From Molecular Mechanisms to Clinical Applications

Call for Papers

Volume-10 | Issue-5

Last date : 27-Oct-2026

Best International Journal
Open Access | Peer Reviewed | Best International Journal | Indexing & IF | 24*7 Support | Dedicated Qualified Team | Rapid Publication Process | International Editor, Reviewer Board | Attractive User Interface with Easy Navigation

Journal Type : Open Access

First Update : Within 7 Days after submittion

Submit Paper Online

For Author

Research Area


Fucoidan as a Marine-Derived Therapeutic: From Molecular Mechanisms to Clinical Applications


Latife Ceyda Irkin



Latife Ceyda Irkin "Fucoidan as a Marine-Derived Therapeutic: From Molecular Mechanisms to Clinical Applications" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-10 | Issue-4, August 2026, pp.1358-1367, URL: https://www.ijtsrd.com/papers/ijtsrd142192.pdf

Fucoidan is a heterogeneous group of sulfated, fucose-rich polysaccharides predominantly isolated from brown seaweeds, including Fucus vesiculosus, Undaria pinnatifida, Cladosiphon okamuranus, Sargassum spp., and Laminaria spp. During the last several decades, fucoidan has attracted considerable interest in biomedical research because of its broad range of biological activities, including anti-inflammatory, immunomodulatory, anticoagulant, antithrombotic, antioxidant, antiviral, cardioprotective, metabolic, and anticancer effects. Importantly, fucoidan should not be regarded as a single chemically defined active pharmaceutical ingredient. Rather, the term describes a structurally diverse family of sulfated polysaccharides whose biological properties vary according to algal source, extraction and purification procedures, molecular weight, monosaccharide composition, degree and pattern of sulfation, and glycosidic linkage. This structural heterogeneity represents one of the principal challenges in translating experimental findings into clinical applications. Preclinical investigations have demonstrated that fucoidan can modulate several signaling pathways involved in inflammation, tumor growth, apoptosis, angiogenesis, metastasis, oxidative stress, immune responses, and coagulation. In oncology, experimental evidence is particularly extensive, with animal and cell-based studies suggesting inhibitory effects on tumor proliferation, angiogenesis, invasion, and metastatic dissemination. However, clinical evidence remains considerably more limited. A double-blind randomized controlled trial in 54 patients with metastatic colorectal cancer found a significantly higher disease-control rate when low-molecular-weight fucoidan was administered as a supplement to chemotherapy and targeted therapy, but no significant improvement in overall survival, progression-free survival, objective response rate, quality of life, or adverse-event outcomes was demonstrated. A systematic review of fucoidan as supplemental therapy in cancer patients identified only four eligible clinical studies involving 118 patients and concluded that the clinical evidence remained inconsistent and was limited by small sample sizes and methodological heterogeneity. Human studies investigating immunomodulatory effects, osteoarthritis, metabolic disease, and liver dysfunction have similarly produced preliminary but insufficient evidence for routine therapeutic use. Fucoidan appears to be generally well tolerated in short-term human studies, although potential anticoagulant effects warrant caution in patients receiving anticoagulant or antiplatelet medications. Contemporary research increasingly focuses not only on fucoidan as a direct therapeutic agent but also on its incorporation into nanoparticles, hydrogels, films, and other drug-delivery platforms. Thus, as of 2026, fucoidan should be considered a promising marine-derived bioactive polymer and investigational therapeutic platform rather than an established treatment for cancer or other major diseases. Future clinical development will require rigorous structural characterization, pharmaceutical standardization, pharmacokinetic studies, well-designed randomized controlled trials, and clear differentiation between specific fucoidan preparations.

Fucoidan, phaeophyta, cancer, inflammation, pharmacology, clinical trials.


IJTSRD142192
Volume-10 | Issue-4, August 2026
1358-1367
IJTSRD | www.ijtsrd.com | E-ISSN 2456-6470
Copyright © 2019 by author(s) and International Journal of Trend in Scientific Research and Development Journal. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (http://creativecommons.org/licenses/by/4.0)

International Journal of Trend in Scientific Research and Development - IJTSRD having online ISSN 2456-6470. IJTSRD is a leading Open Access, Peer-Reviewed International Journal which provides rapid publication of your research articles and aims to promote the theory and practice along with knowledge sharing between researchers, developers, engineers, students, and practitioners working in and around the world in many areas like Sciences, Technology, Innovation, Engineering, Agriculture, Management and many more and it is recommended by all Universities, review articles and short communications in all subjects. IJTSRD running an International Journal who are proving quality publication of peer reviewed and refereed international journals from diverse fields that emphasizes new research, development and their applications. IJTSRD provides an online access to exchange your research work, technical notes & surveying results among professionals throughout the world in e-journals. IJTSRD is a fastest growing and dynamic professional organization. The aim of this organization is to provide access not only to world class research resources, but through its professionals aim to bring in a significant transformation in the real of open access journals and online publishing.

Thomson Reuters
Google Scholer
Academia.edu

ResearchBib
Scribd.com
archive

PdfSR
issuu
Slideshare

WorldJournalAlerts
Twitter
Linkedin